---
slug: 'novo-nordisk-dcf-valuation'
date: '11/29/2025'
title: 'A discounted cash flow valuation of Novo Nordisk'
subtitle: 'Novo Nordisk went from breifly being Europe's largest company by market cap to declining 60% less than 6 months. A century-old enterprise , NVO is investing heavily by acquisitons, CapEX, and  R&D. NVO's online prescription delivery business and international revenue segmant is showing impressive growth. Let's analyze Novo Nordisk fundamental and conduct an intrinsic valuation of the company.'
categories: ['NVO', 'Novo Nordisk', 'Denmark', 'DCF Valuation', 'Signals', 'Valuation']
image: 'https://preview.redd.it/an-intrinsic-discounted-cash-flow-valuation-of-novo-nordisk-v0-3vb55nukya4g1.png?width=1587&format=png&auto=webp&s=32fe1bd929e5fbe311dcbf87674cce898cbc366e'
author: 'Kanchan'
---

## Novo Nordisk

Ozempic Approvals: The initial FDA approval was granted for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.Â  A new indication was approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established heart disease
